Leishmania-induced IRAK-1 inactivation is mediated by SHP-1 interacting with an evolutionarily conserved KTIM motif

Issa Abu-Dayyeh1, Marina Tiemi Shio, Shintaro Sato

  • 1Department of Microbiology and Immunology, McGill University, Montréal, Québec, Canada.

Insights

Leishmania parasites exploit the host

Area of Science:

  • Immunology
  • Molecular Biology
  • Parasitology

Background:

  • Leishmania parasites manipulate macrophage (MØ) signaling to suppress innate immunity and inflammation.
  • Previous work showed heightened inflammation in MØ deficient in Src homology 2 domain-containing protein tyrosine phosphatase (SHP-1).

Purpose of the Study:

  • To investigate if Leishmania uses SHP-1 to inactivate Toll-like receptor (TLR) signaling kinases, specifically IL-1 receptor-associated kinase 1 (IRAK-1).

Main Methods:

  • Investigated the interaction between SHP-1 and IRAK-1 upon Leishmania infection.
  • Identified the IRAK-1 motif responsible for SHP-1 binding and inactivation.
  • Examined other TLR signaling kinases for similar motifs and interactions.

Main Results:

  • SHP-1 directly binds to and inactivates IRAK-1's kinase activity, preventing further TLR activation and MØ function.
  • Discovered a conserved 'Kinase Tyrosyl-based Inhibitory Motif' (KTIM) in IRAK-1 mediating the SHP-1 interaction.
  • Identified KTIM motifs in other TLR pathway kinases like Erk1/2 and IKKalpha/beta, which also interact with SHP-1.

Conclusions:

  • Leishmania parasites exploit host SHP-1 to directly inhibit IRAK-1 via the conserved KTIM motif.
  • This mechanism allows pathogens to dampen the host's innate immune response.
  • The KTIM motif represents a conserved host-pathogen interaction point in innate immunity signaling.

Related Concept Videos

Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...